The following is a summary of “Relevance of patient-centered actigraphy measures in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a qualitative interview study,” ...

Pulmonary angiography, specifically the computed tomographic version, is the gold standard for diagnosing lung embolism.

may lead to pulmonary hypertension, a lethal complication of chronic pulmonary thromboembolism. There are few viable treatment options for pulmonary hypertension, but pulmonary ...

Treprostinil is under clinical development by United Therapeutics and currently in Phase III for Idiopathic Pulmonary Fibrosis.

Chronic thromboembolism can provoke severe pulmonary hypertension if thrombi fail to undergo recanalization or lysis. This occurs in <1% of patients with thromboembolic disease. [12] ...

The top articles about pulmonary arterial hypertension (PAH) in 2024 included FDA approvals, the effect of salt substitutes ...

Mosliciguat is under clinical development by Bayer and currently in Phase I for Kidney Disease (Nephropathy). According to GlobalData, Phase I drugs for Kidney Disease (Nephropathy) have a 71% phase ...

CT neck showed focal nodular thickening in the left false vocal cord and thrombus in the right main pulmonary artery. The subsequent CT pulmonary angiogram performed revealed right pulmonary ...

Physician researchers found 39 weeks of gestation is optimal for delivery in mothers with chronic hypertension. A collaborative study from physician researchers at the University of Cincinnati ...

In the era of DOACs, risk for CTEPH following pulmonary embolism is affected by multiple factors, including gender and heart load.